Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

Academic Article


  • Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • DeVincenzo JP; Hall CB; Kimberlin DW; S├ínchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JAA
  • Start Page

  • 975
  • End Page

  • 978
  • Volume

  • 190
  • Issue

  • 5